Introduction

The Functional Assessment of Cancer Therapy – General (FACT-G-27) is one of the most widely recognized and extensively validated patient-reported outcome measures for assessing health-related quality of life (HRQoL) in individuals diagnosed with cancer. Developed by David Cella and colleagues as the core instrument of the Functional Assessment of Chronic Illness Therapy (FACIT) measurement system, the FACT-G-27 provides a comprehensive evaluation of the physical, emotional, social, and functional impact of cancer and its treatment. Because quality of life has become a central outcome in modern oncology, the FACT-G-27 is routinely used in clinical practice, clinical trials, and health outcomes research to monitor patients’ well-being, evaluate treatment effectiveness, and support patient-centered clinical decision-making. As the foundation of numerous disease-specific FACT questionnaires, it has become an international standard for measuring quality of life across a wide range of cancer populations.

Description

The Functional Assessment of Cancer Therapy – General consists of 27 items organized into four core domains that collectively capture the multidimensional nature of health-related quality of life. Physical Well-Being (PWB) assesses physical symptoms, pain, fatigue, and disease-related discomfort. Social/Family Well-Being (SWB) evaluates perceived support from family members, friends, and the broader social environment. Emotional Well-Being (EWB) measures psychological responses to cancer, including anxiety, fear, emotional distress, and uncertainty about the future. Functional Well-Being (FWB) examines the individual’s ability to perform daily activities, maintain independence, and preserve meaningful roles despite illness. The questionnaire typically requires only 5–10 minutes to complete, making it highly practical for routine clinical monitoring as well as large multicenter research studies. Its balanced assessment of physical, psychosocial, and functional health provides clinicians and researchers with a comprehensive picture of the patient’s overall quality of life throughout the cancer care continuum.

Data Analysis and Interpretation

The Functional Assessment of Cancer Therapy – General produces standardized quantitative data that facilitate comprehensive evaluation of cancer-related quality of life across its four principal domains. Subscale scores allow independent assessment of physical, social, emotional, and functional well-being, while the total FACT-G score provides an overall measure of health-related quality of life. The instrument is widely employed to examine treatment-related changes over time, compare therapeutic interventions, evaluate supportive care programs, and investigate associations between quality of life and clinical, demographic, psychosocial, or biological variables. Because the FACT-G-27 generates standardized psychometric data, it is suitable for descriptive statistical analyses, reliability assessment using Cronbach’s alpha, test–retest reliability analysis, exploratory and confirmatory factor analysis (EFA and CFA), correlation analysis, multiple regression, mediation and moderation analysis, structural equation modeling (SEM), longitudinal analyses, and responsiveness studies assessing clinically meaningful change. According to the available documentation, the instrument demonstrates excellent psychometric performance, including high internal consistency, strong test–retest reliability, robust convergent and discriminant validity, sensitivity to clinically significant changes, and the ability to distinguish between patients at different stages of disease and functional status. Furthermore, the FACT-G has been translated into more than 60 languages and extensively validated across numerous countries and cultural settings, making it one of the most internationally accepted quality-of-life measures in oncology.

Purpose

The primary purpose of the Functional Assessment of Cancer Therapy – General is to provide an objective, multidimensional evaluation of the quality of life experienced by individuals living with cancer. The instrument is specifically designed to assess the overall impact of cancer and its treatment on patients’ daily lives, monitor treatment-related side effects, evaluate clinical progress during therapy, compare different therapeutic approaches, assess the effectiveness of novel anticancer treatments, facilitate patient-centered clinical decision-making, and support scientific research investigating health-related quality of life and treatment outcomes.

Scoring

The Functional Assessment of Cancer Therapy – General consists of 27 items, each rated on a five-point Likert scale ranging from 0 (“Not at all”) to 4 (“Very much”). The total score is calculated by summing the four subscale scores after applying reverse scoring to designated items according to the official FACIT scoring guidelines, ensuring consistent interpretation across all responses. The instrument has a maximum total score of 108 points. Higher scores indicate better health-related quality of life, whereas lower scores reflect greater physical, emotional, social, and functional burden associated with cancer and its treatment. This standardized scoring system enables reliable monitoring of changes over time and meaningful comparisons across patient groups and clinical studies.

Applications

The Functional Assessment of Cancer Therapy – General is extensively used in clinical trials of novel anticancer therapies, quality-of-life assessment across all cancer types, longitudinal monitoring of patients receiving chemotherapy, immunotherapy, radiotherapy, targeted therapy, and surgical treatment, as well as in palliative care services, oncology hospitals, specialized cancer centers, epidemiological research, and patient-reported outcome studies. The instrument also plays a critical role in evaluating supportive care interventions designed to improve patients’ quality of life throughout the cancer trajectory. Owing to its exceptional psychometric properties, international validation, and broad applicability, the FACT-G-27 has become a benchmark instrument for assessing oncology outcomes and comparing treatment strategies in both clinical practice and scientific research worldwide.